Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest's Celexa Adds Warning On Dose-Dependent QT Prolongation

This article was originally published in The Pink Sheet Daily

Executive Summary

The labeling revision, which reflects the results of a thorough QT study, makes Celexa the first drug in the SSRI/SNRI class of antidepressants to include a general warning about QT interval effects.

You may also be interested in...

Amylin's Once-Weekly Bydureon Clears Major Cardiac Safety Hurdle

Extensive data on immediate and extended release exenatide can be "leveraged and applied" to speed development of a once-monthly injectable, which is ready for Phase III.

AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions

The medullary thyroid cancer drug's Risk Evaluation and Mitigation Strategy requires mandatory enrollment and certification of prescribers and pharmacists, which should help ensure the drug is used primarily in patients with symptomatic, progressive disease.

Propoxyphene Marketing Halted By FDAAA-Required QT Safety Study

The opioid, marketed under the Darvon and Darvocet brands and in generic form, has the ignominious distinction of being the first drug pulled from the market based on results of a post-marketing safety study required under the 2007 law.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts